论文部分内容阅读
目的研究雌二醇屈螺酮治疗绝经期综合征的疗效及安全性。方法选取2013年4月—2015年2月收治的96例绝经期综合征患者,采用随机数表分为对照组和观察组,两组各48例。对照组患者给予安慰剂治疗,观察组患者给予雌二醇屈螺酮治疗,均持续用药治疗3个疗程。观察两组治疗效果和不良反应症状发生情况。结果治疗后观察组症状改善Greene(17.5±5.8)分,明显低于对照组(P<0.05);观察组治疗后E2为(76.8±9.4)pmol/ml,明显高于对照组(P<0.05);TG为(2.2±0.5)mmol/L、SBP为(126.5±5.6)mm/Hg、FBG为(5.7±0.4)mmol/L,均显著低于对照组(P<0.05);对照组、观察组不良反应率分别为10.42%、6.25%,无统计学意义(P>0.05)。结论雌二醇屈螺酮能有效改善绝经期综合症患者的潮热潮红等症状,提高体内雌性激素水平和调节血脂、降低血压血糖水平,且治疗未出现明显的不良反应症状,是临床治疗较为安全有效的药物。
Objective To study the efficacy and safety of estradiol drospirenone in the treatment of menopausal syndrome. Methods 96 cases of menopausal syndrome admitted from April 2013 to February 2015 were randomly divided into control group and observation group with 48 cases in each group. Patients in the control group were given placebo, while patients in the observation group were given estradiol drospirenone for 3 months. The two groups were observed the treatment effect and adverse reaction symptoms. Results After treatment, Greene (17.5 ± 5.8) points in observation group were significantly lower than those in control group (P <0.05); E2 in observation group was significantly higher than that in control group (76.8 ± 9.4) pmol / ml ) Were significantly lower than those in the control group (P <0.05). TG was 2.2 ± 0.5 mmol / L, SBP was (126.5 ± 5.6) mm / Hg and FBG was 5.7 ± 0.4 mmol / L, The adverse reaction rates in the observation group were 10.42% and 6.25%, respectively, with no significant difference (P> 0.05). Conclusions Estradiol drospirenone can effectively improve symptoms such as hot flashes and flushing in patients with menopausal syndrome, increase estrogen levels in vivo, regulate blood lipid level and lower blood pressure and blood glucose levels, and there are no obvious adverse reactions in treatment. Safe and effective medicine.